A growing list of biomarkers, e.g., α-smooth muscle actin (α-SMA), S100A4/fibroblast specific protein 1 (FSP-1), fibroblast activation protein (FAP), etc., have been used to define activated CAFs (Hu et al., 2022) and CAFs are a potential therapeutic target for cancer treatment. Here, S100A4 is linked to cancer.